Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
APOA1 antisense RNA (APOA1-AS)
- Target
- APOA1-AS
- Molecular classification
- Long non-coding RNA (lncRNA), Natural antisense transcript (NAT)
01
Overview
APOA1 antisense RNA (APOA1-AS) is a long non-coding natural antisense transcript situated opposite the APOA1 gene in the apolipoprotein gene cluster, chromosome 11q23.3[9]. It negatively regulates APOA1 transcription—primarily in the liver, small intestine, and colon—by promoting suppressive epigenetic modifications that repress APOA1 mRNA synthesis. Dysregulation of APOA1-AS is implicated in decreased HDL production and increased risk of cardiovascular and metabolic diseases. Experimental modulation of APOA1-AS, such as with antisense oligonucleotides, is being investigated as a therapeutic strategy to upregulate protective APOA1 protein expression in relevant disease states[7][9][1].
- Other names
- APOA1-AS RNAApolipoprotein A1 antisense RNA
02
Mechanism of action
Antisense oligonucleotides targeting APOA1-AS inhibit its function, thereby de-repressing APOA1 expression through modulation of suppressive epigenetic marks and altered transcriptional silencing[7][9].
03
Biological functions
Gene regulation (epigenetic silencing)Transcriptional repression of APOA1Modulation of lipid metabolism
04
Disease associations
Cardiovascular disease (e.g., hypoalphalipoproteinemia, atherosclerosis)Hypertension (association with blood pressure regulation)Preeclampsia (upregulation in placental tissues in affected individuals)Other metabolic and inflammatory conditions (potential, based on gene cluster effects)
05
Safety considerations
Potential concerns in therapeutic targeting include off-target gene regulationrisk of disrupting lipid metabolismunintended epigenetic effectsfull safety profiles for antisense approaches targeting APOA1-AS have not been established
06
Interacting drugs
Antisense oligonucleotides (ASOs)
07
Biomarkers
Serum APOA1-AS RNA levels (e.g., elevated in preeclampsia and certain cardiovascular conditions)related changes in APOA1 protein levels
Beyond the preview
Go deeper on APOA1 antisense RNA (APOA1-AS).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APOA1 antisense RNA (APOA1-AS).